



Article

# Antioxidant and Anticholinesterase Activities of *Macrosphyra Longistyla* (DC) Hiern Relevant in the Management of Alzheimer's Disease

Taiwo O. Elufioye<sup>1,\*</sup> , Chidimma G. Chinaka<sup>2</sup> and Adebola O. Oyedeji<sup>1</sup><sup>1</sup> Department of Chemistry, Walter Sisulu University, Mthatha 5117, South Africa; aoyedeji@wsu.ac.za<sup>2</sup> Department of Pharmacognosy, Faculty of Pharmacy, University of Ibadan, Ibadan 200284, Nigeria; chinakachidmma@gmail.com

\* Correspondence: telufioye@wsu.ac.za or toonitaiwo@yahoo.com

Received: 3 June 2019; Accepted: 20 July 2019; Published: 16 September 2019



**Abstract:** *Macrosphyra longistyla* has been used in many traditional systems of medicine for its anti-hemorrhagic, antidiabetic, anti-ulcer, and anti-diarrhea properties. The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitions of the crude methanol extracts and its various partitioned fractions were determined by a modified method of Ellman. An evaluation of the antioxidant activity was carried out using 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging, ferric reducing power, and nitric oxide scavenging assays. The total flavonoids were estimated based on the aluminum chloride method, while the total tannins and phenolics were estimated based on the vanillin-HCl and Folin-Ciocalteu method, respectively. The ethyl acetate fraction had the highest DPPH radical scavenging activity, and the highest ferric reducing power with a concentration providing 50% inhibition (IC<sub>50</sub>) of 0.079 mg/mL and 0.078 mg/mL, respectively, while the crude methanol extract had the highest nitric oxide scavenging activity with an IC<sub>50</sub> of 0.008 mg/mL. The methanol extract had the highest phenolics and flavonoids contents, while the aqueous fraction had the highest tannin content. The crude methanol extract had the best AChE and BuChE inhibitory action, with an IC<sub>50</sub> of 0.556 µg/mL and 5.541 µg/mL, respectively, suggesting that the plant had a better AChE inhibiting potential. A moderate correlation was observed between the phenolic content and DPPH radical scavenging, NO radical scavenging, and AChE inhibitory activities ( $r^2 = 0.439$ ,  $0.430$ , and  $0.439$ , respectively), while a high correlation was seen between the flavonoid content and these activities ( $r^2 = 0.695$ ,  $0.724$ , and  $0.730$ , respectively), and the ferric reducing antioxidant power correlated highly with the proautocyanidin content ( $r^2 = 0.801$ ). Gas chromatography mass spectrometry (GCMS) revealed decanoic acid methyl ester (24.303%), 11,14-eicosadienoic acid methyl ester (16.788%), linoelaidic acid (10.444%), pentadecanoic acid (9.300%), and 2-methyl-hexadecanal (9.285%). Therefore, we suggest that *M. longistyla* contain bioactive chemicals, and could be a good alternative for the management of Alzheimer's and other neurodegenerative diseases.

**Keywords:** *Macrosphyra longistyla*; cholinesterase; antioxidant; total phenolic; total flavonoid

## 1. Introduction

Alzheimer's disease and other neurodegenerative conditions are usually characterized by the slow, but progressive, dysfunction and loss of neurons in the central nervous system [1]. About 55 million people are suffering from one form of neurodegenerative disease (ND) or another, with an expected rise in this figure with increasing age of the population [2,3]. Despite the volume of research on the pathogenesis of neurodegenerative conditions, appropriate treatment is yet to be found [4]. However, several factors, including aging [5] and some pathological conditions, such

as impaired mitochondrial function [6], aggregated proteins deposit [7], neuroinflammation [8], cholinergic deficit [9], and oxidative stress [10], have been associated with NDs. Thus, the management of NDs involves addressing one or more of the associated conditions. The currently available therapies for Alzheimer's disease (AD) are cholinesterase inhibitors such as rivastigmine and donepezil, which only reduce disease progression and provide symptomatic relieve [11]. Thus, efforts are still being made to find alternative and better therapeutic options.

*Macrosphyra longistyla* is a shrub found in several tropical countries. It has long, arching stems that are about 4 m long [12]. *M. longistyla* has been used traditionally as an antihemorrhagic in Benin [13], as an antidiabetic in Nigeria and Côte d'Ivoire [14,15], as a contraceptive and for the restoration of fertility [16], for ulcers [17], and for diarrhea [18]. Fresh wildy-collected leaves are eaten as a vegetable by the Gourmantché, Aïzo, and Cotafon people in Benin [19]. It is also widely consumed in Togo [20]. The leaves have been suggested an indigenous food ingredient for complementary food formulations to combat infant malnutrition [21]. To the best of our knowledge, the chemical constituents and biological activity of this plant have not been reported in the literature. This study therefore investigates its anticholinesterase and anti-oxidant potentials, as well as phytochemical characterization.

## 2. Materials and Methods

### 2.1. Plant Material

The leaves of *Macrosphyra longistyla* were collected from Agbogi village in Osun State in December 2017. The plant was identified and authenticated by Mr. Odewo of the Forest Herbarium Ibadan (FHI), with voucher number FHI 112042. The voucher specimen were deposited at the herbarium of the Department of Pharmacognosy, University of Ibadan.

### 2.2. Plant Extraction and Partitioning

The leaves were air-dried and pulverized. About 2.25 kg of the powdered leaf was macerated using 100% methanol. The extract was filtrated using a Buchner funnel, and concentrated in vacuo so as to obtain a crude methanol extract. Then, 80 g of the crude methanol extract was partitioned into *n*-hexane, ethyl acetate, and water, to obtain the respective fractions, which were concentrated in vacuo and used for the subsequent experiments. The percentage yield of both extract and fractions were determined.

### 2.3. Phytochemical Screening

The preliminary phytochemical screening of the crude methanol extract was carried out using standard procedures. These include tests for alkaloids using Dragendorff and Wagner reagents, the Borntrager's test for anthraquinones, and a ferric chloride test for phenolic compounds [22,23].

### 2.4. Determination of the Total Phenol Content (TPC)

The total phenol content in the methanolic extract and various fractions of *M. longistyla* were determined based on a previously described procedure [24]. Then, 2.5 mL of 10% Folin–Ciocalteu's reagent was mixed with 2 mL of 2% sodium carbonate solution ( $\text{Na}_2\text{CO}_3$ ), followed by the addition of 0.5 mL of methanolic extract and fractions of *M. longistyla* (1 mg/mL). The mixture was incubated at 45 °C for 15 min, and absorbance was taken at 765 nm. The quantification was done with respect to the standard of gallic acid at different concentrations (1, 0.5, 0.25, 0.125, 0.063, and 0.031 mg/mL). The content of the total phenolic compounds was calculated based on a standard curve prepared using gallic acid and expressed as milligrams of gallic acid equivalent (GAE) per gram of sample.

### 2.5. Determination of Total Flavonoid Contents (TFC)

The total flavonoid content was determined using the aluminum chloride colorimetric method [25]. In this method, 1 mL of crude extract or fractions of *M. longistyla* were mixed with 3 mL of methanol,

followed by 0.2 mL of 10% aluminum chloride ( $\text{AlCl}_3$ ), 0.2 mL of potassium acetate (1 M), and 5.6 mL of distilled water, and left at room temperature for 30 min. Absorbance was taken at 420 nm. Quantification was done with respect to the standard of gallic acid at different concentrations (1, 0.5, 0.25, 0.125, 0.063, and 0.031 mg/mL). The total phenolic content was calculated based on a standard curve prepared using gallic acid, and expressed as milligrams of gallic acid equivalent (GAE) per gram of sample.

#### 2.6. Determination of Pro-Anthocyanidin Content (PAC)

The vanillin-HCl method was used for the quantitative determination of condensed tannins (proanthocyanidins) [26]. In this method, 3 mL of 4% vanillin in methanol, and 1.5 mL of hydrochloric acid (HCl) was added to 0.5 mL of extract/fractions (1 mg/mL). The mixture was vortexed thoroughly and allowed to stand for 15 min at room temperature. Absorbance was read at 500 nm. A calibration curve was prepared using a standard gallic acid solution. All of the results were expressed as mg gallic acid equivalents (GAE) per gram of sample.

#### 2.7. DPPH (2,2-Diphenyl-1-Picrylhydrazyl Hydrate) Radical Scavenging Assay

The radical scavenging ability of the fractions was determined using the stable radical DPPH (2,2-diphenyl-1-picrylhydrazyl hydrate), as previously described [27]. In this assay, 1 mL of 0.1 mM DPPH was mixed with 1 mL of crude extract and fractions of *M. longistyla* at different concentrations (1, 0.5, 0.25, 0.125, 0.063, and 0.031 mg/mL), as well as the positive controls (ascorbic acid and 2,6-di-tert-butyl-4-methylphenol (DDM)) at different concentrations (1, 0.5, 0.25, and 0.125 mg/mL). The reaction was vortexed and left in the dark at room temperature for 30 min, after which the absorbance was taken at 517 nm. The percentage inhibition was calculated as follows:

$$I\% = [(A_{\text{blank}} - A_{\text{sample}})/A_{\text{blank}}] \times 100$$

where  $A_{\text{blank}}$  is the absorbance of the control reaction (containing all reagents except the test compound), and  $A_{\text{sample}}$  is the absorbance of the test compound. The sample concentration providing 50% inhibition ( $\text{IC}_{50}$ ) was also calculated.

#### 2.8. Nitric Oxide (NO) Scavenging Assay

The nitric oxide scavenging assay was carried out as previously described [28]. First, 2 mL of sodium nitroprusside was mixed with 0.5 mL of phosphate buffer pH 7.4 and 0.5 mL of different concentrations of extract (0.0031–1.0 mg/mL). The mixture was incubated at 25 °C for 150 min, and an initial absorbance ( $A_0$ ) was taken at 540 nm. Thereafter, 0.5 mL of the incubated mixture was mixed with 1 mL of a sulfanilic acid reagent and 1 mL of naphthylethylenediamine dichloride (0.1% w/v), and incubated at room temperature for 30 min, before another absorbance ( $A_1$ ) was taken at 540 nm. The same reaction mixture without the extract but with the equivalent amount of methanol served as the negative control. Ascorbic acid and DDM at various concentrations were used as the standard. All of the experiments were in triplicates. The percentage nitrite radical scavenging activity of the extracts and standard were calculated using the following formula:

$$\% \text{ inhibition of NO} = [A_0 - A_1]/A_0 \times 100$$

where  $A_0$  is the absorbance before the reaction, and  $A_1$  is the absorbance after the reaction.

#### 2.9. Ferric Reducing Antioxidant Assay

The reducing power was determined according to the method of Oyaizu [29]. Substances with a reducing ability react with potassium ferricyanide ( $\text{Fe}^{3+}$ ) to form potassium ferrocyanide ( $\text{Fe}^{2+}$ ), which then reacts with ferric chloride to form a ferric ferrous complex that has an absorption maximum at

700 nm. Briefly, 0.2 mL of various concentrations of plant extract and fractions was mixed with 0.2 mL of phosphate buffer and 0.2 mL of potassium ferricyanide. The mixture was vortexed and incubated at 50 °C for 20 min. After cooling, 0.2 mL of 10% trichloroacetic acid (TCA) was then added to the mixture and centrifuged at 4500 rpm for 10 min. Then, 100 µL of the upper solution was mixed with 20 µL of the ferric chloride solution and 100 µL of distilled water. The absorbance was taken at 700 nm. The control was prepared in a similar manner, but without the test sample. Ascorbic acid and DDM at various concentrations were used as the standard. The experiments were done in triplicates.

### 2.10. Cholinesterase Inhibitory Assay

Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitions were determined spectrophotometrically using acetylcholine iodide and butyrylcholine iodide as substrates, respectively, by a modified method of Ellman [30]. The serial dilutions of the fractions were subjected to this test using eserine and donepezil as the positive control. Then, 5 mg of both the extract and fractions were dissolved in 1 mL of methanol. Serial dilutions of each sample were done in order to obtain the final concentrations of 1, 0.5, 0.25, 0.125, and 0.0625 mg/mL, while the positive controls (eserine and donepezil) were also diluted serially to obtain the final concentrations of 0.1, 0.05, 0.025, 0.0125, 0.00625, and 0.003125 mg/mL. Thereafter, 20 µL of each concentration was pipetted into the micro plates, followed by 240 µL of the phosphate buffer (pH 8) and 20 µL of the enzyme, which was then vortexed. The plates were then incubated at 37 °C for 30 min. After incubation, 20 µL of 25 mM of the substrate (acetylthiocholine iodide (ATChI) or butyrylthiocholine chloride (BTChCl)) was added to the reaction mixture, followed by the addition of 20 µL of 10 mM 5, 5'-Dithiobis-2-nitrobenzoic acid (DTNB). The hydrolysis of acetylcholine iodide or butyrylthiocholine chloride was determined spectrophotometrically at 412 nm. The assay was carried out in triplicates, with methanol as the negative control. The percentage inhibition was computed using the following formula:

$$\frac{\Delta a - \Delta b}{\Delta a} \times 100$$

where  $\Delta a$  is the change in absorbance of the negative control, and  $\Delta b$  is the change in absorbance of the sample.

### 2.11. Gas Chromatography Mass Spectrometry (GCMS) Analysis

One microliter (1 µL) of the sample diluted in hexane was analyzed on a Bruker 450 gas chromatography-300 mass spectrometer (GCMS) system operating in EI mode at 70 eV, equipped with a HP-5 MS fused silica capillary system with a 5% phenylmethylsiloxane stationary phase. The capillary column parameter was 30 m by 0.25 mm, while the film thickness was 0.25 µm. The initial temperature of the column was set at 70 °C, and heated to 240 °C at a rate of 5 °C/min, with the final temperature kept at 450 °C. The run time was 66.67 min, and helium was used as the carrier gas at a flow rate of 1 min/min. The split ratio was 100:1. The scan time was 78 min, with a scanning range of 35 to 450 amu.

### 2.12. Statistical Analysis

All of the data were analyzed using GraphPad Prism 6.0, and were expressed as mean ± standard error of the mean (SEM). The correlation and regression analysis of the activities (Y) versus the total phytochemical content (X) were carried out using the online Quest Graph™ Linear, Logarithmic, Semi-Log Regression Calculator [31].

## 3. Results and Discussion

*M. longistyla* has been reportedly used for managing different ailments in traditional medicine [13–18]. In an ethnomedical survey carried out by us, the plant was mentioned as a memory enhancer.

Thus, the present study was carried out to investigate its phytochemical content, as well as evaluate the antioxidant and cholinesterase inhibitory activities of the extracts and partitioned fractions.

The preliminary phytochemical screening of the methanol extract revealed the presence of tannins, flavonoids, phenolics, terpenoids, and saponins. Anthraquinones and alkaloids were, however, found absent in the plant (Table 1).

**Table 1.** Phytochemical screening results of *Macrosphyra longistyla*.

Tests	Observations	Inferences
1. Alkaloids		
a. Dragendorff	Deep yellow color	Alkaloid absent
b. Wagner test	Orange color	Alkaloid absent
2. Anthraquinones		
a. Borntrager's test	Milky color	Anthraquinone absent
3. Flavonoids	Yellow coloration	Flavonoids present
4. Phenols	Dark coloration	Phenols present
5. Tannins	Blue black coloration	Tannin present
6. Saponin	Frothing which disappear after sometime	Saponin present
7. Terpenoid	Dark green coloration	Terpenoids present

The percentage yield of the extract and fractions (expressed as weight of extract/fraction relative to the weight of the initial plant material) ranged from 4.70% to 40.00%, with the highest being the aqueous fraction (Table 2). This suggests that the polar solvent was able to extract more constituents, probably because of the solubility of the polar compounds present in the plant material.

**Table 2.** The total phenolics, flavonoids, and anthocyanidins content in the extract and fractions of *M. longistyla*.

Assays	ME	HF	EF	AF
% Yield	6.18	4.70	7.11	40.00
Total phenolics (mg GAE/g)	18.30 ± 0.04	7.56 ± 0.12	16.06 ± 0.13	9.02 ± 0.02
Total flavonoids (mg GAE/g)	16.07 ± 0.14	5.02 ± 0.01	10.49 ± 0.014	11.62 ± 0.01
Total tannins (mg GAE/g)	24.44 ± 0.32	2.99 ± 0.06	9.12 ± 0.17	26.11 ± 0.02

Data are expressed as mean ± standard error of the mean (SEM;  $n = 3$ ). GAE—gallic acid equivalent; ME—methanol extract; HF—hexane fraction; EF—ethyl acetate fraction; AF—aqueous fraction.


Furthermore, the content of the phenols (TPC), flavonoids (TFC), and the tannins (PAC) was estimated quantitatively. The TPC, as determined by the Folin–Ciocalteu method, ranged from  $7.56 \pm 0.12$  to  $18.30 \pm 0.04$  mg GAE/g of extract (Table 2). Both the crude extract and the various fractions had an appreciable total phenolic content, with the methanol extract and the ethyl acetate fractions having the highest TPC, while the *n*-hexane fraction had the least TPC. The total flavonoid and proanthocyanidin contents, also reported as mg GAE/g of extract, showed that the TFC ranged from  $5.02 \pm 0.01$  to  $16.07 \pm 0.14$  mg GAE/g of extract, while the PAC ranged from  $2.99 \pm 0.06$  to  $26.11 \pm 0.02$ . In both cases, the hexane fraction had the least amount (Table 2).

Phenolic compounds are present in plant tissues and serve as antioxidants [32], because of the presence of hydroxyl groups, which are responsible for their scavenging ability. Thus, they are capable of reacting with active oxygen radicals such as hydroxyl radicals [33]. Flavonoids are polyphenolic compounds, and are responsible for some of the health benefits of vegetable and fruits [34]. They are known to play an active role in the quenching of free radicals, because of their redox properties [35].

Tannins, however, are a high molecular weight polyphenolic that have also been implicated as antioxidants [36].

The antioxidant activity of the extract and fractions was evaluated by the DPPH and NO radical scavenging activity, as well as the ferric reducing power, while the AChE inhibitory activity was evaluated by Ellman's colorimetric assay.

DPPH is usually reduced by a hydrogen donating compound, leading to its change in color, from deep violet to light yellow, which can be monitored spectrophotometrically [37]. The DPPH radical scavenging activity results are as shown in Figure 1, while the  $IC_{50}$ —the concentration of antioxidant (extract/fractions) required for 50% scavenging of DPPH radicals—values are given in Table 3. From the results, the ethyl acetate fraction had the highest activity, with an  $IC_{50}$  value of 0.078.



**Figure 1.** 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging activity of extract and fractions of *M. longistyla*. Data are expressed as mean  $\pm$  standard deviation (SD;  $n = 3$ ). ME—methanol extract; HF—hexane fraction; EF—ethyl acetate fraction; AF—aqueous fraction; DDM—2,6-di-tert-butyl-4-methylphenol.


**Table 3.** The concentration providing 50% inhibition ( $IC_{50}$ ) values of the different antioxidant assays.

Assays	$IC_{50}$					
	ME	HF	EF	AF	Ascorbic Acid	DDM
DPPH scavenging	0.090	0.363	0.079	0.089	0.006	0.050
NO scavenging	0.008	5.678	0.056	0.010	0.072	0.063
Ferric reducing	0.051	0.087	0.078	0.009	0.053	0.003

ME—methanol extract; HF—hexane fraction; EF—ethyl acetate fraction; AF—aqueous fraction; DDM—2,6-di-tert-butyl-4-methylphenol; DPPH—1,1-diphenyl-2-picryl-hydrazyl; NO—nitric oxide.


Nitric oxide is important in the regulation of several physiological processes, and several diseases have been associated with a high concentration of NO [38]. The nitric oxide scavenging activity can be determined by estimating for nitrate and nitrite, using the Greiss Illosvoy reaction [39]. At a physiological pH (7.2), sodium nitroprusside decomposes in an aqueous solution to produce NO, which reacts with oxygen to form stable products—nitrate and nitrite. Scavengers of NO compete with oxygen, leading to a reduced production of nitrite ions [40].

In the nitric oxide scavenging assay, all of the extract and fractions exhibited a good scavenging effect, with the methanol extract having the best scavenging effect ( $IC_{50} = 0.008$ ), followed by an aqueous fraction ( $IC_{50} = 0.010$ ) and then the ethyl acetate fraction ( $IC_{50} = 0.056$ ; Figure 2 and Table 3).



**Figure 2.** Nitric oxide (NO) radical scavenging activity of the extract and fractions of *M. longistyla*. Data are expressed as mean  $\pm$  SD ( $n = 3$ ). ME—methanol extract; HF—hexane fraction; EF—ethyl acetate fraction; AF—aqueous fraction; DDM—2,6-di-tert-butyl-4-methylphenol.

Ferric reducing power is well linked with antioxidant activity [41], and compounds with a reducing effect are usually electron donors that can reduce oxidized intermediates of lipid peroxidation processes, thus acting as primary or secondary antioxidants [33]. In the ferric reducing antioxidant assay, the methanol extract, aqueous fraction, and the ethyl acetate fraction had good reducing activity (Figure 3), with  $IC_{50}$  values of 0.051, 0.009, and 0.078 respectively.




**Figure 3.** Ferric reducing activity of the extract and fractions of *M. longistyla*. Data are expressed as mean  $\pm$  SD ( $n = 3$ ). ME—methanol extract; HF—hexane fraction; EF—ethyl acetate fraction; AF—aqueous fraction; DDM—2,6-di-tert-butyl-4-methylphenol.


On the whole, a better antioxidant activity was observed in the polar fractions, and this could be because of the abundant presence of major secondary metabolites, such as tannins and flavonoids, in these fractions, as supported by the higher TPC and TFC in these fractions. Phenolics are free-radical terminators [33], thus having protective effects against many infectious and neuro degenerative diseases such as AD [42].

The inhibition of cholinesterase enzymes is considered promising in the management of neurological and neurodegenerative disorders such as AD, senile dementia, ataxia, and myasthenia gravis, where a deficit in cholinergic neurotransmission is often observed [43,44]. Compounds with a dual inhibitory effect on AChE and BuChE are also considered better, as BuChE also plays a minor role in the regulation of AChE [45,46].

In this study, the methanol extract inhibited the acetylcholinesterase enzyme the most, followed by the ethyl acetate and aqueous fractions, with respective percentage inhibitions of  $81.629 \pm 0.02$ ,  $76.985 \pm 0.04$ , and  $71.778 \pm 0.01$  (Figure 4). The hexane fraction had the least inhibitory action, suggesting that the active constituents are likely to be polar. The study also suggests a better inhibition of AChE as compared to BuChE, as both the crude extract and the various fractions had a lower percentage inhibition and higher  $IC_{50}$  values in the later enzyme (Figure 5 and Table 4).



**Figure 4.** Acetylcholinesterase inhibitory activity of the extract and fractions of *M. longistyla*. Data are expressed as mean  $\pm$  SD ( $n = 3$ ). ME—methanol extract; HF—hexane fraction; EF—ethyl acetate fraction; AF—aqueous fraction.



**Figure 5.** Butyrylcholinesterase inhibitory activity of the extract and fractions of *M. longistyla*. Data are expressed as mean  $\pm$  SD ( $n = 3$ ). ME—methanol extract; HF—hexane fraction; EF—ethyl acetate fraction; AF—aqueous fraction.

**Table 4.** IC<sub>50</sub> values for the cholinesterase inhibitory assay. AChE—acetylcholinesterase; BuChE—butyrylcholinesterase.

Assays	IC <sub>50</sub>					
	ME	HF	EF	AF	Eserin	Donepezil
AChE	0.556	25.871	0.914	0.846	0.002	0.001
BuChE	5.541	11.957	23.338	ND	0.002	0.001

ND: Not determined.

The cholinesterase inhibitory activity of several medicinal plants has been reported in the literature [47–51]. Also, antioxidants such as vitamin E and vitamin C have been reportedly associated with a decrease in AD incidence and prevalence, [52] and AD patients on high doses of antioxidants were reported to have a slower rate of cognitive deterioration [53]. Thus, the good antioxidant and anticholinesterase activities of polar fractions in this study suggest that these fractions are good sources of phenolic compounds, with potential cholinesterase inhibitory and antioxidant properties that may find usefulness in the management of AD. This is the first report of such activities in *Macrosphyra longistyla*.

We also correlated the phytochemical content with the observed activities of the plant. Several pharmacological effects of the plant extract such, as being anti-inflammatory, antioxidant, and antimicrobial, have also been associated with the presence of phenolic compounds [54,55], and  $r^2$  values have been used to show the relationship between the phytochemical constituents and activities of medicinal plants [56]. There was a moderate correlation between the total phenolic content and the DPPH and NO radical scavenging, as well as the AChE inhibitory activities ( $r^2 = 0.439, 0.430,$  and  $0.439$ , respectively). However, a better correlation was observed between the flavonoid content and these activities ( $r^2 = 0.695, 0.724,$  and  $0.730$ , respectively), while the ferric reducing antioxidant power correlated with the proautocyanidin content ( $r^2 = 0.801$ ; Table 5).

**Table 5.** Correlation of the total phenolic, total flavonoid, and proautocyanidin contents with antioxidant and anticholinesterase activities.

Assays	$r^2$ Values		
	Total Phenolics	Total Flavonoids	Proautocyanidin
DPPH scavenging	0.439	0.695	0.515
NO scavenging	0.430	0.724	0.558
Ferric reducing	0.012	0.276	0.801
AChE inhibition	0.439	0.730	0.557
BuChE inhibition	0.00154	0.131	0.325

Finally, the identification of possible compounds in the non-polar (hexane) fraction using GC-MS revealed the presence of twenty-three compounds (Table 6). The most abundant was decanoic acid methyl ester (24.303%), followed by 11,14-eicosadienoic acid methyl ester (16.788%), linoelaidic acid (10.444%), pentadecanoic acid (9.300%), and 2-methyl-hexadecanal (9.285%).

**Table 6.** Compounds identified through gas chromatography mass spectrometry (GCMS).

S/N	Name of Identified Compounds	Retention Time (min)	% Abundance	Molecular Formula	Class of Compound	Reported Biological Effect	References
1	2,6,8-trimethyl-decane	27.084	0.084	C <sub>13</sub> H <sub>28</sub>	Alkane	Antifungal	[57]
2	2-methyl-hexadecanal	30.833	9.285	C <sub>17</sub> H <sub>34</sub> O	Aldehyde	Antifungal	[58]
3	Z,Z,Z-1,4,6,9-nonadecatetraene	34.147	0.349	C <sub>19</sub> H <sub>32</sub>	Alkene	Antioxidant	[59]
4	2-dodecanone	34.831	0.357	C <sub>12</sub> H <sub>24</sub> O	Aliphatic ketones	Nematocidal	[60]
5	2-pentadecanone	35.591	1.630	C <sub>15</sub> H <sub>30</sub> O	Ketone	Cytotoxic and repellent	[61,62]
6	17-octadecanal	39.211	0.119	C <sub>18</sub> H <sub>36</sub> O	Long-chain aldehyde	NR	NR
7	Hexadecanoic acid	39.564	0.152	C <sub>16</sub> H <sub>32</sub> O <sub>2</sub>	Saturated fatty acid	Anticancer and anthelmintic	[63,64]
8	2-methyl-dodecanoic acid	43.071	0.283	C <sub>11</sub> H <sub>22</sub> O <sub>2</sub>	Fatty acid	Antimicrobial	[65]
9	Neophytadiene	43.482	0.109	C <sub>20</sub> H <sub>38</sub>	Sesquiterpene	Anti-inflammatory	[66]
10	2-nonadecanone	43.611	1.942	C <sub>19</sub> H <sub>38</sub> O	Alkanone	Antimicrobial	[67]
11	Decanoic acid methyl ester	46.414	24.303	C <sub>11</sub> H <sub>22</sub> O <sub>2</sub>	Fatty acid ester	Antimicrobial	[68]
12	Phytol	47.053	0.202	C <sub>20</sub> H <sub>40</sub> O	Diterpene alcohol	Antinociceptive, antioxidant, and anticholinesterase	[69,70]
13	Eicosanoic acid ethyl ester	48.585	5.265	C <sub>22</sub> H <sub>44</sub> O <sub>2</sub>	Fatty acid	Anticancer	[71]
14	Pentadecanoic acid	48.592	9.300	C <sub>15</sub> H <sub>30</sub> O <sub>2</sub>	Saturated fatty acid	Anthelmintic	[64]
15	tetradecanoic acid-12-methyl-methyl ester	49.580	0.048	C <sub>16</sub> H <sub>32</sub> O <sub>2</sub>	Fatty acid	Anticancer and antifungal	[72,73]
16	11,14-eicosadienoic acid methyl ester	51.562	16.788	C <sub>21</sub> H <sub>38</sub> O <sub>2</sub>	Fatty acid	Antioxidant and anti-amylase	[74]
17	8,11,14-ecosatrienoic acid	51.712	2.299	C <sub>20</sub> H <sub>34</sub> O <sub>2</sub>	Omega fatty acid	Atopic dermatitis and malignant hypertension	[75,76]
18	Z-methyl-hexadec-11-enoate	51.963	4.204	C <sub>17</sub> H <sub>32</sub> O <sub>2</sub>	Fatty acid methyl ester	Antimicrobial	[77]
19	Dodecanoic acid-10-methyl-methyl ester	52.643	1.957	C <sub>14</sub> H <sub>28</sub> O <sub>2</sub>	Fatty acid methyl ester	Anticoagulant	[78]
20	Linoelaidic acid	53.559	10.444	C <sub>18</sub> H <sub>32</sub> O <sub>2</sub>	Omega-6 trans fatty acid	Anticholinesterase, anti-mycobacterium, anticancer, and antioxidant	[79–82]
21	Z,E-3,13-octadecadien-1-ol	53.763	2.707	C <sub>18</sub> H <sub>34</sub> O	Fatty alcohol	Antimicrobial	[83]
22	(Z)-methyl-Heptadec-9-enoate	53.953	0.179	C <sub>18</sub> H <sub>34</sub> O <sub>2</sub>	Fatty acid	Antibiotic	[84]
23	Hexadecanoic acid-2-methyl-methyl ester	54.615	1.139	C <sub>18</sub> H <sub>36</sub> O <sub>2</sub>	Fatty acid methyl esters	Antimicrobial and antioxidant	[85]

NR: Not reported. The various identified compounds have been reported to have different biological effects, such as being antimicrobial, antioxidant, anticoagulant, anticholinesterase, anticancer, and anthelmintic. All of these ultimately contribute to the overall activity of the plant.

#### 4. Conclusions

This study revealed the antioxidant and anticholinesterase activities of the compounds present in *M. longistyla*, and suggest the potential use of extracts from this plant for the management of neurodegenerative conditions. The polar fractions had the highest antioxidants and anticholinesterase constituents, which can be further exploited. Also, the GCMS analysis identified the compounds likely to contribute to the observed activities.

**Author Contributions:** Conceptualization, T.O.E.; data curation, C.G.C.; funding acquisition, T.O.E.; investigation, C.G.C.; methodology, T.O.E.; project administration, A.O.O.; resources, A.O.O.; supervision, T.O.E.; writing (original draft), C.G.C.; writing (review and editing), T.O.E. and A.O.O.

**Funding:** This work is based on the research supported in part by the National Research Foundation of South Africa (Grant number UID 110789) and the TETFUND Research Project (RP) intervention of Nigeria.

**Acknowledgments:** The authors hereby acknowledge the financial support of Walter Sisulu University.

**Conflicts of Interest:** Authors declare no conflict of interest.

## References

1. Amor, S.; Puentes, F.; Baker, D.; Van Der Valk, P. Inflammation in neurodegenerative diseases. *Immunology* **2010**, *129*, 154–169. [[CrossRef](#)]
2. Chen, H.; Kwong, J.C.; Copes, R.; Tu, K.; Villeneuve, P.J.; Van Donkelaar, A.; Hystad, P.; Martin, R.V.; Murray, B.J.; Jessiman, B.; et al. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: A population-based cohort study. *Lancet* **2017**, *389*, 718–726. [[CrossRef](#)]
3. Prince, M.; Guerchet, M.; Prina, M. *The Epidemiology and Impact of Dementia: Current State and Future Trends*; World Health Organization: Geneva, Switzerland, 2015.
4. Solanki, I.; Parihar, P.; Mansuri, M.L.; Parihar, M.S. Flavonoid-Based Therapies in the Early Management of Neurodegenerative Diseases. *Adv. Nutr.* **2015**, *6*, 64–72. [[CrossRef](#)] [[PubMed](#)]
5. Tan, C.-C.; Yu, J.-T.; Tan, M.-S.; Jiang, T.; Zhu, X.-C.; Tan, L. Autophagy in aging and neurodegenerative diseases: Implications for pathogenesis and therapy. *Neurobiol. Aging* **2014**, *35*, 941–957. [[CrossRef](#)] [[PubMed](#)]
6. Johri, A.; Beal, M.F. Mitochondrial Dysfunction in Neurodegenerative Diseases. *J. Pharmacol. Exp. Ther.* **2012**, *342*, 619–630. [[CrossRef](#)] [[PubMed](#)]
7. Takalo, M.; Salminen, A.; Soininen, H.; Hiltunen, M.; Haapasalo, A. Protein aggregation and degradation mechanisms in neurodegenerative diseases. *Am. J. Neurodegener. Dis.* **2013**, *2*, 1–14.
8. Chen, W.-W.; Zhang, X.; Huang, W.-J. Role of neuroinflammation in neurodegenerative diseases (Review). *Mol. Med. Rep.* **2016**, *13*, 3391–3396. [[CrossRef](#)] [[PubMed](#)]
9. Schliebs, R.; Arendt, T. The cholinergic system in aging and neuronal degeneration. *Behav. Brain Res.* **2011**, *221*, 555–563. [[CrossRef](#)] [[PubMed](#)]
10. Butterfield, D.A.; Swomley, A.M.; Sultana, R. Amyloid  $\beta$ -Peptide (1–42)-Induced Oxidative Stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression. *Antioxid. Redox Signal.* **2013**, *19*, 823–835. [[CrossRef](#)]
11. Kumar, A.; Singh, A. A review on Alzheimer's disease pathophysiology and its management: An update. *Pharmacol. Rep.* **2015**, *67*, 195–203. [[CrossRef](#)]
12. Keay, R.W. *Randia and Gardenia in West Africa*; Bulletin du Jardin botanique de l'Etat, Bruxelles/Bulletin van den Rijksplantentuin: Brussel, Belgium, 1958; pp. 15–72.
13. Klotoé, J.; Dougnon, T.V.; Koudouvo, K.; Atègbo, J.-M.; Loko, F.; Akoègninou, A.; Aklikokou, K.; Dramane, K.; Gbeassor, M. Ethnopharmacological Survey on Antihemorrhagic Medicinal Plants in South of Benin. *Eur. J. Med. Plants* **2013**, *3*, 40–51. [[CrossRef](#)]
14. Olabanji, S.; Adebajo, A.; Omobuwajo, O.; Ceccato, D.; Buoso, M.; Moschini, G. PIXE analysis of some Nigerian anti-diabetic medicinal plants (II). *Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. Atoms* **2014**, *318*, 187–190. [[CrossRef](#)]
15. Konkon, N.G.; Ouatarra, D.; Kpan, W.B.; Kouakou, T.H. Medicinal plants used for treatment of diabetes by traditional practitioners in the markets of Abidjan district in Côte d'Ivoire. *J. Med. Plants Stud.* **2017**, *5*, 39–48.
16. Soladoye, M.O.; Ikotun, T.; Chukwuma, E.C.; Ariwaodo, J.O.; Ighanesebor, G.A.; Agbo-Adediran, O.A.; Owolabi, S.M. Our plants, our heritage: Preliminary survey of some medicinal plant species of Southwestern University Nigeria Campus, Ogun State, Nigeria. *Annu. Biol. Res.* **2013**, *4*, 27–34.
17. Allabi, A.C.; Busia, K.; Ekanmian, V.; Bakiono, F. The use of medicinal plants in self-care in the Agonlin region of Benin. *J. Ethnopharmacol.* **2011**, *133*, 234–243. [[CrossRef](#)]
18. Agbankpé, A.J.; Dougnon, T.V.; Bankolé, H.S.; Yèhouénon, B.; Yédomonhan, H.; Lègonou, M.; Dougnon, T.J. Etude ethnobotanique des légumes feuilles thérapeutiques utilisés dans le traitement des diarrhées au sud-Bénin (Afrique de l'Ouest). *Int. J. Biol. Chem. Sci.* **2014**, *8*, 1784–1795. [[CrossRef](#)]

19. Achigan-Dako, E.G.; Pasquini, M.W.; Assogba Komlan, F.; N'danikou, S.; Yédomonhan, H.; Dansi, A.; Ambrose-Oji, B. *Traditional Vegetables in Benin*; Institut National des Recherches Agricoles du Bénin, Imprimeries du CENAP: Cotonou, Benin, 2010; p. 174.
20. Atato, A.; Wala, K.; Batawila, K.; Lamien, N.; Akpagana, K. Edible wild fruit highly consumed during food shortage period in Togo: State of knowledge and conservation status. *J. Life Sci.* **2011**, *5*, 1046–1057.
21. Chadare, F.J.; Madode, Y.E.; Fanou-Fogny, N.; Kindossi, J.M.; Ayosso, J.O.; Honfo, S.H.; Kayodé, A.P.; Linnemann, A.R.; Hounhouigan, D.J. Indigenous food ingredients for complementary food formulations to combat infant malnutrition in Benin: A review. *J. Sci. Food Agric.* **2018**, *98*, 439–455. [[CrossRef](#)]
22. Sofowora, A. Screening Plants for Bioactive Agents. In *Medicinal Plants and Traditional Medicinal in Africa*, 2nd ed.; Spectrum Books Ltd.: Ibadan, Nigeria, 1993; pp. 134–156.
23. Trease, G.E.; Evans, W.C. *Pharmacognosy*, 15th ed.; Saunders Publishers: London, UK, 2002; pp. 221–393.
24. Singleton, V.L.; Rossi, J.A. Colorimetric of total phenolics with phosphomolybdic-phosphotungstic acid reagents. *Am. J. Enol. Vinic.* **1965**, *16*, 144–158.
25. Köksal, E.; Gülçin, I. Antioxidant activity of cauliflower (*Brassica oleracea* L.). *Turk. J. Agric. For.* **2008**, *32*, 65–78.
26. Broadhurst, R.B.; Jones, W.T. Analysis of condensed tannins using acidified vanillin. *J. Sci. Food Agric.* **1978**, *29*, 788–794. [[CrossRef](#)]
27. Brand-Williams, W.; Cuvelier, M.; Berset, C. Use of a free radical method to evaluate antioxidant activity. *LWT* **1995**, *28*, 25–30. [[CrossRef](#)]
28. Aiyegoro, O.A.; Okoh, A.O. Preliminary phytochemical screening and In vitro antioxidant activities of the aqueous extract of *Helichrysum longifolium* DC. *BMC Complement. Altern. Med.* **2010**, *10*, 21. [[CrossRef](#)] [[PubMed](#)]
29. Oyaizu, M. Studies on products of browning reaction. Antioxidative activities of products of browning reaction prepared from glucosamine. *Jpn. J. Nutr. Diet.* **1986**, *44*, 307–315. [[CrossRef](#)]
30. Ellman, G.L.; Courtney, K.; Andres, V.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* **1961**, *7*, 88–95. [[CrossRef](#)]
31. Quest Graph™. *Linear, Logarithmic, Semi-Log Regression Calculator*; AAT Bioquest, Inc.: Sunnyvale, CA, USA. Available online: <https://www.aatbio.com/tools/linear-logarithmic-semi-log-regression-online-calculator> (accessed on 20 May 2019).
32. Shahidi, F.; Ambigaipalan, P. Phenolics and polyphenolics in foods, beverages and spices: Antioxidant activity and health effects—A review. *J. Funct. Foods* **2015**, *18*, 820–897. [[CrossRef](#)]
33. Brewer, M. Natural Antioxidants: Sources, Compounds, Mechanisms of Action, and Potential Applications. *Compr. Rev. Food Sci. Food Saf.* **2011**, *10*, 221–247. [[CrossRef](#)]
34. Han, R.-M.; Zhang, J.-P.; Skibsted, L.H. Reaction Dynamics of Flavonoids and Carotenoids as Antioxidants. *Molecules* **2012**, *17*, 2140–2160. [[CrossRef](#)]
35. Wolfe, K.; Wu, X.; Liu, R.H. Antioxidant Activity of Apple Peels. *J. Agric. Food Chem.* **2003**, *51*, 609–614. [[CrossRef](#)]
36. Koleckar, V.; Kubikova, K.; Řeháková, Z.; Kuca, K.; Jun, D.; Jahodář, L.; Opletal, L. Condensed and Hydrolysable Tannins as Antioxidants Influencing the Health. *Mini-Rev. Med. Chem.* **2008**, *8*, 436–447. [[CrossRef](#)]
37. Kedare, S.B.; Singh, R.P. Genesis and development of DPPH method of antioxidant assay. *J. Food Sci. Technol.* **2011**, *48*, 412–422. [[CrossRef](#)] [[PubMed](#)]
38. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric Oxide and Peroxynitrite in Health and Disease. *Physiol. Rev.* **2007**, *87*, 315–424. [[CrossRef](#)] [[PubMed](#)]
39. Garrat, D.C. *The Quantitative Analysis of Drugs*; Chapman and Hall Ltd.: Tokyo, Japan, 1964; Volume 3, pp. 456–458.
40. Al-Majedy, Y.K.; Al-Amiery, A.A.; Kadhum, A.A.H.; Mohamad, A.B. Antioxidant Activities of 4-Methylumbelliferone Derivatives. *PLoS ONE* **2016**, *11*, 0156625. [[CrossRef](#)] [[PubMed](#)]
41. Benzie, I.F.; Strain, J. Ferric reducing/antioxidant power assay: Direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. In *Methods in Enzymology*; Elsevier BV: Amsterdam, The Netherlands, 1999; Volume 299, pp. 15–27.

42. Aliev, G.; Obrenovich, M.E.; Reddy, V.P.; Shenk, J.C.; Moreira, P.I.; Nunomura, A.; Zhu, X.; Smith, M.A.; Perry, G. Antioxidant Therapy in Alzheimer's Disease: Theory and Practice. *Mini-Rev. Med. Chem.* **2008**, *8*, 1395–1406. [[CrossRef](#)] [[PubMed](#)]
43. Schneider, L.S. Treatment of Alzheimer's disease with cholinesterase inhibitors. *Clin. Geriatr. Med.* **2001**, *17*, 337–358. [[CrossRef](#)]
44. Ranjan, N.; Kumari, M. Acetylcholinesterase inhibition by medicinal plants: A Review. *Ann. Plant Sci.* **2017**, *6*, 1640–1644. [[CrossRef](#)]
45. Venneri, A.; McGeown, W.J.; Shanks, M.F. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. *NeuroReport* **2005**, *16*, 107–110. [[CrossRef](#)]
46. Khan, I.; Nisar, M.; Khan, N.; Saeed, M.; Nadeem, S.; Rehman, F.U.; Ali, F.; Karim, N.; Kaleem, W.A.; Qayum, M.; et al. Structural insights to investigate Conyopodioid as a dual cholinesterase inhibitor from *Asparagus adscendens*. *Fitoterapia* **2010**, *81*, 1020–1025. [[CrossRef](#)]
47. Mathew, M.; Subramanian, S. In Vitro Screening for Anti-Cholinesterase and Antioxidant Activity of Methanolic Extracts of Ayurvedic Medicinal Plants Used for Cognitive Disorders. *PLoS ONE* **2014**, *9*, e86804. [[CrossRef](#)]
48. Owokotomo, I.; Ekundayo, O.; Abayomi, T.; Chukwuka, A. In-vitro anti-cholinesterase activity of essential oil from four tropical medicinal plants. *Toxicol. Rep.* **2015**, *2*, 850–857. [[CrossRef](#)]
49. Samaradivakara, S.P.; Samarasekera, R.; Handunnetti, S.M.; Weerasena, O.J. Cholinesterase, protease inhibitory and antioxidant capacities of Sri Lankan medicinal plants. *Ind. Crop. Prod.* **2016**, *83*, 227–234. [[CrossRef](#)]
50. Sheeja, M.D.; Beema, S.R.; Karutha, P.S.; Pandima, D.K. Cholinesterase inhibitory, anti-amyloidogenic and neuroprotective effect of the medicinal plant *Grewia tiliaefolia*—An in vitro and in silico study. *Pharm. Biol.* **2017**, *55*, 381–393. [[CrossRef](#)] [[PubMed](#)]
51. Ovais, M.; Ayaz, M.; Khalil, A.T.; Shah, S.A.; Jan, M.S.; Raza, A.; Shahid, M.; Shinwari, Z.K. HPLC-DAD finger printing, antioxidant, cholinesterase, and  $\alpha$ -glucosidase inhibitory potentials of a novel plant *Oxana nana*. *BMC Complement. Altern. Med.* **2018**, *18*, 1. [[CrossRef](#)] [[PubMed](#)]
52. Steele, M.; Stuchbury, G.; Münch, G. The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. *Exp. Gerontol.* **2007**, *42*, 28–36. [[CrossRef](#)] [[PubMed](#)]
53. Mecocci, P.; Polidori, M.C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. *Biochim. Biophys. Acta Mol. Basis Dis.* **2012**, *1822*, 631–638. [[CrossRef](#)] [[PubMed](#)]
54. Zhang, L.; Ravipati, A.S.; Koyyalamudi, S.R.; Jeong, S.C.; Reddy, N.; Smith, P.T.; Bartlett, J.; Shanmugam, K.; Münch, G.; Wu, M.J. Antioxidant and Anti-inflammatory Activities of Selected Medicinal Plants Containing Phenolic and Flavonoid Compounds. *J. Agric. Food Chem.* **2011**, *59*, 12361–12367. [[CrossRef](#)] [[PubMed](#)]
55. Gülçin, İ.; Huyut, Z.; Elmastaş, M.; Aboul-Enein, H.Y. Radical scavenging and antioxidant activity of tannic acid. *Arab. J. Chem.* **2010**, *3*, 43–53. [[CrossRef](#)]
56. Babbar, N.; Oberoi, H.S.; Uppal, D.S.; Patil, R.T. Total phenolic content and antioxidant capacity of extracts obtained from six important fruit residues. *Food Res. Int.* **2011**, *44*, 391–396. [[CrossRef](#)]
57. Hussain, A.; Tian, M.-Y.; He, Y.-R.; Bland, J.M.; Gu, W.-X. Behavioral and electrophysiological responses of *Coptotermes formosanus* Shiraki towards entomopathogenic fungal volatiles. *Biol. Control* **2010**, *55*, 166–173. [[CrossRef](#)]
58. Choi, H.-S. Analysis of the Terpenoids from *Syneilesis palmata* Essential Oil and the Variation of the Sesquiterpene Compounds by Harvest Year. *Korean J. Food Nutr.* **2013**, *26*, 287–294. [[CrossRef](#)]
59. Palani, S.; Raja, S.; Kumar, R.P.; Selvaraj, R.; Kumar, B.S. Evaluation of phytoconstituents and anti-nephrotoxic and antioxidant activities of *Monochoria vaginalis*. *Pak. J. Pharm. Sci.* **2011**, *24*, 293–301. [[PubMed](#)]
60. Ntalli, N.G.; Manconi, F.; Leonti, M.; Maxia, A.; Caboni, P. Aliphatic Ketones from *Ruta chalepensis* (Rutaceae) Induce Paralysis on Root Knot Nematodes. *J. Agric. Food Chem.* **2011**, *59*, 7098–7103. [[CrossRef](#)] [[PubMed](#)]
61. Walia, M.; Mann, T.S.; Kumar, D.; Agnihotri, V.K.; Singh, B. Chemical Composition and In Vitro Cytotoxic Activity of Essential Oil of Leaves of *Malus domestica* Growing in Western Himalaya (India). *Evid. Based Complement. Altern. Med.* **2012**, *2012*, 649727. [[CrossRef](#)] [[PubMed](#)]
62. Innocent, E.; Gikonyo, N.K.; Nkunya, M.H. Repellency property of long chain aliphatic methyl ketones against *Anopheles gambiae* s.s. *Tanzan. J. Health Res.* **2008**, *10*, 50–54.
63. Manosroi, A.; Jantrawut, P.; Sainakham, M.; Manosroi, W.; Manosroi, J. Anticancer activities of the extract from Longkong (*Lansium domesticum*) young fruits. *Pharm. Biol.* **2012**, *50*, 1397–1407. [[CrossRef](#)] [[PubMed](#)]

64. Hernández-Villegas, M.; Borges-Argáez, R.; Rodríguez-Vivas, R.; Torres-Acosta, J.; Méndez-González, M.; Cáceres-Farfán, M.; Torres-Acosta, J.F.D.J. In vivo anthelmintic activity of *Phytolacca icosandra* against *Haemonchus contortus* in goats. *Veter Parasitol.* **2012**, *189*, 284–290. [[CrossRef](#)] [[PubMed](#)]
65. Hamza, F.; Zinjarde, S. Marine Biodiversity As a Resource for Bioactive Molecules As Inhibitors of Microbial Quorum Sensing Phenotypes. In *Biotechnological Applications of Quorum Sensing Inhibitors*; Springer Science and Business Media LLC: Berlin/Heidelberg, Germany, 2018; pp. 329–350.
66. Carretero, M.; López-Pérez, J.L.; Abad, M.; Bermejo, P.; Tillet, S.; Israel, A.; Noguera, P.B. Preliminary study of the anti-inflammatory activity of hexane extract and fractions from *Bursera simaruba* (Linneo) Sarg. (Burseraceae) leaves. *J. Ethnopharmacol.* **2008**, *116*, 11–15. [[CrossRef](#)]
67. Silici, S.; Kutluca, S. Chemical composition and antibacterial activity of propolis collected by three different races of honeybees in the same region. *J. Ethnopharmacol.* **2005**, *99*, 69–73. [[CrossRef](#)]
68. Conley, A.J.; Kabara, J.J. Antimicrobial Action of Esters of Polyhydric Alcohols. *Antimicrob. Agents Chemother.* **1973**, *4*, 501–506. [[CrossRef](#)]
69. Santos, C.C.; Salvadori, M.S.; Mota, V.G.; Costa, L.M.; de Almeida, A.A.; de Oliveira, G.A.; Costa, J.P.; de Sousa, D.P.; de Freitas, R.M.; de Almeida, R.N. Antinociceptive and antioxidant activities of phytol in vivo and in vitro models. *Neurosci. J.* **2013**, *2013*, 949452. [[CrossRef](#)]
70. Elufioye, T.O.; Obuotor, E.M.; Agbedahunsi, J.M.; Adesanya, S.A. Cholinesterase inhibitory activity and structure elucidation of a new phytol derivative and a new cinnamic acid ester from *Pycnanthus angolensis*. *Rev. Bras. Farm.* **2016**, *26*, 433–437. [[CrossRef](#)]
71. Ghalib, R.M.; Hashim, R.; Sulaiman, O.; Mehdi, S.H.; Anis, Z.; Rahman, S.Z.; Ahamed, B.K.; Abdul Majid, A.M. Phytochemical analysis, cytotoxic activity and constituents–activity relationships of the leaves of *Cinnamomum iners* (Reinw. ex Blume-Lauraceae). *Nat. Prod. Res.* **2012**, *26*, 2155–2158. [[PubMed](#)]
72. Gecibesler, I.H.; Yaghluglu, A.S.; Gul, F.; Temirturk, M.; Demirtas, I. Phytochemicals of *Chrysophthalmum montanum* (DC.) Boiss. Roots and their antiproliferative activities Against HeLa and C6 Cell Lines. *Proc. Natl. Acad. Sci. India Sect. B Biol. Sci.* **2019**, *89*, 145–154. [[CrossRef](#)]
73. El-Din, S.M.M.; Mohyeldin, M.M. Component Analysis and Antifungal Activity of the Compounds Extracted from Four Brown Seaweeds with Different Solvents at Different Seasons. *J. Ocean Univ. China* **2018**, *17*, 1178–1188. [[CrossRef](#)]
74. Conforti, F.; Menichini, F.; Loizzo, M.R.; Statti, A.G.; Rapisarda, A.; Menichini, F.; Houghton, P.J. Antioxidant,  $\alpha$ -amylase inhibitory and brine-shrimp toxicity studies on *Centaurea centaurium* L. methanolic root extract. *Nat. Prod. Res.* **2008**, *22*, 1457–1466. [[CrossRef](#)]
75. Vakharia, P.P.; Silverberg, J.I. New therapies for atopic dermatitis: Additional treatment classes. *J. Am. Acad. Dermatol.* **2018**, *78*, S76–S83. [[CrossRef](#)]
76. Jíhová, Š.; Kopkan, L.; Husková, Z.; Doleželová, Š.; Neckář, J.; Kujal, P.; Vernerová, Z.; Kramer, H.J.; Sadowski, J.; Kompanowska-Jeziarska, E.; et al. Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: A study in Cyp11a1-Ren-2 transgenic rats. *J. Hypertens.* **2016**, *34*, 2008–2025. [[CrossRef](#)]
77. Sales, D.L.; Oliveira, O.P.; Cabral, M.E.; Dias, D.Q.; Kerntopf, M.R.; Coutinho, H.D.; Costa, J.G.; Freitas, F.R.; Ferreira, F.S.; Alves, R.R.; et al. Chemical identification and evaluation of the antimicrobial activity of fixed oil extracted from *Rhinella jimi*. *Pharm. Biol.* **2015**, *53*, 98–103. [[CrossRef](#)]
78. Nagarjunakonda, S.; Amalakanti, S.; Dhishana, S.R.; Ramaiah, M.; Rajanala, L. GC-MS Analysis of Indrakeeladri Native Medicine used in the Treatment of Stroke. *Pharmacogn. J.* **2017**, *9*, 102–106. [[CrossRef](#)]
79. Sandoval-Montemayor, N.E.; García, A.; Elizondo-Treviño, E.; Garza-González, E.; Alvarez, L.; Camacho-Corona, M.D.R. Chemical Composition of Hexane Extract of *Citrus aurantifolia* and Anti-*Mycobacterium tuberculosis* Activity of Some of Its Constituents. *Molecules* **2012**, *17*, 11173–11184. [[CrossRef](#)]
80. Mormile, R.; Vittori, G.; De Michele, M.; Squarcia, U.; Quaini, F. Linoleic acid and colorectal cancer cell growth suppression: Is the deregulation of mitochondrial surviving the key factor? *Int. J. Colorectal Dis.* **2012**, *27*, 1383–1384. [[CrossRef](#)] [[PubMed](#)]
81. Kim, Y.-S.; Lee, S.-J.; Hwang, J.-W.; Kim, E.-K.; Kim, S.-E.; Kim, E.-H.; Moon, S.-H.; Jeon, B.-T.; Park, P.-J. In vitro protective effects of *Thymus quinquecostatus* Celak extracts on t-BHP-induced cell damage through antioxidant activity. *Food Chem. Toxicol.* **2012**, *50*, 4191–4198. [[CrossRef](#)] [[PubMed](#)]

82. Gok, M.; Zeybek, N.D.; Bodur, E. Butyrylcholinesterase expression is regulated by fatty acids in HepG2 cells. *Chem. Interact.* **2016**, *259*, 276–281. [[CrossRef](#)] [[PubMed](#)]
83. Agboke, A.A.; Attama, A.A. Bioactive components and antibacterial activities of n-hexane extract of *Moringa oleifera* root bark on clinical isolates of methicilin resistant *Staphylococcus aureus*. *Int. J. Curr. Res. Chem. Pharm. Sci.* **2016**, *3*, 1–9.
84. Avis, T.J.; Boulanger, R.R.; Belanger, R.R. Synthesis and Biological Characterization of (Z)-9-Heptadecenoic and (Z)-6-Methyl-9-Heptadecenoic Acids: Fatty Acids with Antibiotic Activity Produced by *Pseudozyma flocculosa*. *J. Chem. Ecol.* **2000**, *26*, 987–1000. [[CrossRef](#)]
85. Wang, J.; Liu, H.; Gao, H.; Zhao, J.; Zhou, L.; Han, J.; Yu, Z.; Yang, F. Antimicrobial and antioxidant activities of the flower essential oil of *Halimodendron halodendron*. *Nat. Prod. Commun.* **2011**, *6*. [[CrossRef](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).